Protocol # GS-US-321-0106: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Compensated Cirrhosis Secon

Project: Research project

Project Details

StatusFinished
Effective start/end date3/14/138/31/19

Funding

  • PPD Development (GS-US-321-0106)
  • Gilead Sciences, Inc. (GS-US-321-0106)